What is self.co?
Established in 2015 by Gintautas Gylys and Tautvydas Gylys, Self.co is at the forefront of digital health and diagnostics, focusing on empowering individuals to comprehend and manage allergy-like symptoms. The firm has developed proprietary molecular testing technology, including advanced microarray-based assays. These assays are designed to analyze allergens and food sensitivities from a small blood sample, offering convenience through at-home collection or utilization of partner clinics. This innovative approach positions Self.co as a key player in the personalized health technology sector, aiming to provide accessible and accurate diagnostic solutions.
How much funding has self.co raised?
self.co has raised a total of $3M across 2 funding rounds:
Grant
$1.6M
Unspecified
$1.4M
Grant (2025): $1.6M with participation from Innovation Agency Lithuania
Unspecified (2025): $1.4M led by Iron Wolf Capital and Coinvest Capital
Key Investors in self.co
Innovation Agency Lithuania
Innovation Agency Lithuania is an entity focused on supporting and developing businesses and innovations within Lithuania, likely providing strategic backing for companies with significant technological advancements.
Iron Wolf Capital
Iron Wolf Capital is a venture capital firm specializing in early-stage AI and deep tech startups in the Baltics and diaspora, suggesting a focus on innovative technology and high-growth potential companies.
Coinvest Capital
Coinvest Capital is a venture capital fund that co-invests with business angels and private funds, aiming to enhance the startup ecosystem in Lithuania, particularly in strategic sectors like Life Sciences.
What's next for self.co?
The recent major strategic investment in Self.co, following substantial enterprise-level capital infusion, indicates a strong market validation and confidence in the company's innovative molecular testing technology. This financing is expected to accelerate the scaling of its operations, further development of its proprietary assays, and expansion into new markets. The company's focus on allergy-like symptoms and food sensitivities addresses a growing consumer need for personalized health insights, positioning Self.co for significant future growth and impact in the digital health landscape.
See full self.co company page
